KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $38.7 million.

  • Halozyme Therapeutics' Other Gross PP&E Adjustments rose 4185.3% to $38.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.7 million, marking a year-over-year increase of 4185.3%. This contributed to the annual value of $25.6 million for FY2024, which is 6063.23% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at $38.7 million for Q3 2025, which was up 4185.3% from $32.9 million recorded in Q2 2025.
  • Halozyme Therapeutics' Other Gross PP&E Adjustments' 5-year high stood at $39.4 million during Q3 2022, with a 5-year trough of $5.2 million in Q4 2022.
  • Over the past 5 years, Halozyme Therapeutics' median Other Gross PP&E Adjustments value was $17.7 million (recorded in 2022), while the average stood at $22.6 million.
  • Within the past 5 years, the most significant YoY rise in Halozyme Therapeutics' Other Gross PP&E Adjustments was 20665.0% (2023), while the steepest drop was 6850.94% (2023).
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Other Gross PP&E Adjustments stood at $15.2 million in 2021, then tumbled by 65.84% to $5.2 million in 2022, then surged by 206.65% to $15.9 million in 2023, then skyrocketed by 60.63% to $25.6 million in 2024, then surged by 51.4% to $38.7 million in 2025.
  • Its Other Gross PP&E Adjustments was $38.7 million in Q3 2025, compared to $32.9 million in Q2 2025 and $32.9 million in Q1 2025.